MEGAN MORIARTY: Open Payments
NPI 1285306332 · LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,706 in 99 payments from 14 companies in 2025. Trend: 2023 $353 · 2024 $804 · 2025 $1,706
Food & beverage: $1,706
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $320 |
| Vanda Pharmaceuticals Inc. | 13 | $319 |
| Janssen Pharmaceuticals, Inc | 19 | $204 |
| Axsome Therapeutics, Inc. | 7 | $162 |
| E.R. Squibb & Sons, L.L.C. | 9 | $154 |
| Neurocrine BioSciences, Inc. | 6 | $123 |
| ABBVIE INC. | 4 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $54 |
Products named: HETLIOZ, REXULTI, INVEGA SUSTENNA, Auvelity, COBENFY, INGREZZA, VRAYLAR, CAPLYTA.
Industry payments across IN — which companies pay providers there.
